ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Update

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 253,000 shares, a decline of 24.2% from the November 15th total of 333,600 shares. Approximately 2.3% of the shares of the company are short sold. Based on an average trading volume of 148,600 shares, the short-interest ratio is presently 1.7 days.

ABVC BioPharma Price Performance

ABVC stock opened at $0.52 on Friday. The firm’s 50-day simple moving average is $0.56 and its 200 day simple moving average is $0.68. The stock has a market cap of $6.68 million, a PE ratio of -0.60 and a beta of 0.72. ABVC BioPharma has a fifty-two week low of $0.41 and a fifty-two week high of $2.45.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.